Comparison
Semaglutide vs cagrilintide
Two different satiety pathways, usually discussed as a pair rather than a choice. One is an approved drug on its own; the other is mostly studied alongside it.
Semaglutide acts on the GLP-1 receptor. Cagrilintide is an amylin analogue working on a separate satiety pathway, which is exactly why most of the literature combines them instead of comparing them.
Cagrilintide's evidence largely comes from that combination. Studied alone it is a less complete picture than semaglutide's, which has a full phase 3 programme and approvals behind it.
The honest framing: this is a comparison people search for and a pairing the research actually tested. The stack page covers the pairing.
| Attribute | Semaglutide | Cagrilintide |
|---|---|---|
| Class | GLP-1 receptor agonist | Amylin analogue |
| Evidence level | Approved | Clinical |
| Dosing frequency | Once weekly | Once weekly |
| Usually run | Alone or with cagrilintide | Almost always with a GLP-1 |
| Most common reported side effects | Nausea, vomiting, constipation | Nausea, injection site reactions |
Things worth knowing
- Gastrointestinal effects limit the dose of both. Titrate two of them at once and you will not be able to tell which one is responsible, or which one to pull back.
- The combination studied in trials was a co-formulated product. Two separate vials at self-chosen doses is not that product.
Full profile
Semaglutide
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and for weight management, dosed once weekly.
Full profile
Cagrilintide
A long-acting amylin analogue in late-stage trials. It works on a different satiety pathway from the GLP-1 drugs. Which is why it is being developed alongside semaglutide rather than against it.
Related
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.